Clinical trials in Nantes – page 67

951 clinical trials in Nantes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Nantes at a glance

951

clinical trials

Research sites2

Quick filters

951 trials in Nantes

Open in trial search

Plasma cell myeloma+1

Not recruiting

Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo

Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Celgene Corp.

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obefazimod
Sponsor:Abivax

Contact Research Centre

Neoplasm

Not recruiting

Study of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors - First human trial to evaluate safety and effectiveness

Registered drugNo placebo

Study of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors - First human trial to evaluate safety and effectiveness

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study of Pirtobrutinib, Venetoclax and Rituximab combination compared to Venetoclax and Rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo

Study of Pirtobrutinib, Venetoclax and Rituximab combination compared to Venetoclax and Rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Loxo Oncology Inc.

Contact Research Centre

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Loxo Oncology Inc.

Contact Research Centre

Haemodialysis

Not recruiting

Study on the Effects of Tacrolimus on Blood Sugar Levels in Patients Undergoing Dialysis Before Kidney Transplantation

Registered drugNo placebo

Study on the Effects of Tacrolimus on Blood Sugar Levels in Patients Undergoing Dialysis Before Kidney Transplantation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tacrolimus
Sponsor:Centre Hospitalier Departemental Vendee

Contact Research Centre

Neuroendocrine tumour+1

Not recruiting

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Octreotide
Sponsor:Advanced Accelerator Applications

Contact Research Centre

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Herpes simplex

Not recruiting

Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

Registered drugNo placebo

Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Cidofovir
Sponsor:AiCuris Anti-infective Cures AG

Contact Research Centre

Chronic lymphocytic leukaemia+2

Not recruiting

Study of Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

InvestigationalNo placebo

Study of Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Loxo Oncology Inc.

Contact Research Centre

Chronic myeloid leukaemia

Not recruiting

Study on Asciminib and Asciminib Hydrochloride for Patients with Chronic Myelogenous Leukemia in Chronic Phase After Two or More Tyrosine Kinase Inhibitors

Registered drugNo placebo

Study on Asciminib and Asciminib Hydrochloride for Patients with Chronic Myelogenous Leukemia in Chronic Phase After Two or More Tyrosine Kinase Inhibitors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Asciminib
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Nantes

What the registry says about research in the country

01 Oncology and Hematology

Advanced research focusing on multiple myeloma, leukemia, and various lymphomas. Studies are evaluating novel treatment combinations and therapeutic approaches for blood cancers.

Multiple Myeloma Treatments
Lymphoma Therapies
Leukemia Management

Innovative trials exploring combinations of targeted therapies and immunotherapies to improve patient outcomes.

02 Infectious Diseases

Comprehensive studies on preventive measures against viral infections, including trials for vaccines targeting CMV, yellow fever, and mpox.

Vaccine Development
Viral Prevention
Immunization Studies

Focus on developing and evaluating new vaccine formulations and delivery methods.

03 Autoimmune Conditions

Research investigating treatments for inflammatory bowel diseases and multiple sclerosis, including innovative approaches like fecal microbiota transplantation.

Crohn's Disease
Ulcerative Colitis
MS Treatment Strategies

Exploring novel therapeutic options and treatment de-escalation strategies.

04 Critical Care Medicine

Studies addressing postoperative care and management of severe conditions in intensive care settings, including burns and immune suppression.

Post-Surgery Care
Burn Treatment
ICU Interventions

Evaluating new approaches to improve patient comfort and outcomes in critical care.

Back to France All countries